NOVEL COMPOUNDS
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KEMP, MARK IAN STOCKLEY, MARTIN LEE MADIN, ANDREW |
| description | The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
La présente invention concerne de nouveaux composés et des procédés de fabrication d'inhibiteurs d'enzymes de désubiquitination (DUB). En particulier, l'invention concerne l'inhibition de l'hydrolase C-terminale de l'ubiquitine 30 ou de la peptidase spécifique de l'ubiquitine 30 (USP30). L'invention concerne en outre l'utilisation d'inhibiteurs de DUB pour le traitement de pathologies impliquant un dysfonctionnement mitochondrial et pour le traitement du cancer. Les composés selon l'invention comportent des composés de formule (I): (I) ou un sel pharmaceutiquement acceptable correspondant, où R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L et A sont tels que définis dans la description. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3008747C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3008747C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3008747C3</originalsourceid><addsrcrecordid>eNrjZOD38w9z9VFw9vcN8A_1cwnmYWBNS8wpTuWF0twM8m6uIc4euqkF-fGpxQWJyal5qSXxzo7GBgYW5ibmzsaEVQAAfycccg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NOVEL COMPOUNDS</title><source>esp@cenet</source><creator>KEMP, MARK IAN ; STOCKLEY, MARTIN LEE ; MADIN, ANDREW</creator><creatorcontrib>KEMP, MARK IAN ; STOCKLEY, MARTIN LEE ; MADIN, ANDREW</creatorcontrib><description>The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
La présente invention concerne de nouveaux composés et des procédés de fabrication d'inhibiteurs d'enzymes de désubiquitination (DUB). En particulier, l'invention concerne l'inhibition de l'hydrolase C-terminale de l'ubiquitine 30 ou de la peptidase spécifique de l'ubiquitine 30 (USP30). L'invention concerne en outre l'utilisation d'inhibiteurs de DUB pour le traitement de pathologies impliquant un dysfonctionnement mitochondrial et pour le traitement du cancer. Les composés selon l'invention comportent des composés de formule (I): (I) ou un sel pharmaceutiquement acceptable correspondant, où R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L et A sont tels que définis dans la description.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230613&DB=EPODOC&CC=CA&NR=3008747C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230613&DB=EPODOC&CC=CA&NR=3008747C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KEMP, MARK IAN</creatorcontrib><creatorcontrib>STOCKLEY, MARTIN LEE</creatorcontrib><creatorcontrib>MADIN, ANDREW</creatorcontrib><title>NOVEL COMPOUNDS</title><description>The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
La présente invention concerne de nouveaux composés et des procédés de fabrication d'inhibiteurs d'enzymes de désubiquitination (DUB). En particulier, l'invention concerne l'inhibition de l'hydrolase C-terminale de l'ubiquitine 30 ou de la peptidase spécifique de l'ubiquitine 30 (USP30). L'invention concerne en outre l'utilisation d'inhibiteurs de DUB pour le traitement de pathologies impliquant un dysfonctionnement mitochondrial et pour le traitement du cancer. Les composés selon l'invention comportent des composés de formule (I): (I) ou un sel pharmaceutiquement acceptable correspondant, où R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L et A sont tels que définis dans la description.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZOD38w9z9VFw9vcN8A_1cwnmYWBNS8wpTuWF0twM8m6uIc4euqkF-fGpxQWJyal5qSXxzo7GBgYW5ibmzsaEVQAAfycccg</recordid><startdate>20230613</startdate><enddate>20230613</enddate><creator>KEMP, MARK IAN</creator><creator>STOCKLEY, MARTIN LEE</creator><creator>MADIN, ANDREW</creator><scope>EVB</scope></search><sort><creationdate>20230613</creationdate><title>NOVEL COMPOUNDS</title><author>KEMP, MARK IAN ; STOCKLEY, MARTIN LEE ; MADIN, ANDREW</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3008747C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>KEMP, MARK IAN</creatorcontrib><creatorcontrib>STOCKLEY, MARTIN LEE</creatorcontrib><creatorcontrib>MADIN, ANDREW</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KEMP, MARK IAN</au><au>STOCKLEY, MARTIN LEE</au><au>MADIN, ANDREW</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NOVEL COMPOUNDS</title><date>2023-06-13</date><risdate>2023</risdate><abstract>The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
La présente invention concerne de nouveaux composés et des procédés de fabrication d'inhibiteurs d'enzymes de désubiquitination (DUB). En particulier, l'invention concerne l'inhibition de l'hydrolase C-terminale de l'ubiquitine 30 ou de la peptidase spécifique de l'ubiquitine 30 (USP30). L'invention concerne en outre l'utilisation d'inhibiteurs de DUB pour le traitement de pathologies impliquant un dysfonctionnement mitochondrial et pour le traitement du cancer. Les composés selon l'invention comportent des composés de formule (I): (I) ou un sel pharmaceutiquement acceptable correspondant, où R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L et A sont tels que définis dans la description.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3008747C |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | NOVEL COMPOUNDS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T20%3A37%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KEMP,%20MARK%20IAN&rft.date=2023-06-13&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3008747C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |